iRhythm Beats Q1 Estimates, Guides Higher, and Shares Jump
iRhythm Holdings Inc (NASDAQ:IRTC) reported first-quarter results after the bell on Wednesday that came in ahead of analyst expectations on both the top and bottom lines. Management also raised its full-year guidance, prompting a notable after-market rally.
Revenue and Earnings: Beating the Street
For the three months ended March 31, 2026, iRhythm posted revenue of $199.4 million, representing a 25.7% increase from $158.7 million in the year-ago period. That figure surpassed the consensus estimate of $197.9 million.
On an adjusted non-GAAP basis, the company reported a net loss of $0.35 per diluted share, which was significantly better than the average analyst forecast of a $0.66 loss. For comparison, the adjusted net loss was $0.95 per share in the same quarter last year.
Key operational metrics from the quarter include:
- Gross Margin: 70.9%, up from 68.8% in Q1 2025, a 210-basis point improvement driven by operational efficiencies and volume scale.
- Net Loss (GAAP): $13.9 million, a sharp improvement from a $30.7 million loss in the prior year.
- Adjusted EBITDA: $14.1 million, or a 7.1% margin, compared to an adjusted loss of $2.6 million in Q1 2025.
- Cash Position: Unrestricted cash, cash equivalents, and marketable securities stood at $549.6 million.
The results highlight a business that continues to scale profitably, with volume-led growth across its Zio portfolio now expanding beyond traditional cardiology into primary care and international markets.
Higher Guidance and Market Reaction
Management raised its full-year 2026 outlook, now expecting revenue in the range of $875 million to $885 million, up from its prior guidance. The midpoint of this new range ($880 million) is slightly above the current analyst consensus of $893.6 million when considering the implied upper end. Perhaps more tellingly, iRhythm also guided for an adjusted EBITDA margin of 12% to 13%, a meaningful improvement from the Q1 run rate of 7.1% and signaling strong operating leverage ahead.
The market immediately responded to the beat-and-raise. In after-hours trading, shares of iRhythm jumped roughly 2.1%, building on a broader uptrend. The stock has already performed strongly ahead of the print, gaining roughly 9.3% over the past month and 6.3% over the last week. The positive after-market move suggests investors are rewarding the company for beating estimates and delivering a higher quality of earnings with expanding margins.
Operational Outlook and Diversification
CEO Quentin Blackford emphasized the company’s successful push into broader care settings and product diversification. "We are increasingly diversified across channels, with meaningful contributions from Zio monitor, Zio AT, innovative partnerships, and international markets," he said.
The company is also advancing its AI-enabled capabilities and expanding into earlier detection, which management believes represents a larger total addressable market. New data was presented at major cardiology conferences (ACC and HRS) during the quarter, underscoring the clinical utility of the Zio portfolio.
For the upcoming second quarter, analysts currently estimate revenue of roughly $222.6 million, with expectations for continued sequential improvement in adjusted profitability.
Analyzing the Numbers
For a deeper look at iRhythm’s historical earnings performance and to access detailed projections and estimates for future quarters, visit the dedicated earnings page and analyst forecasts section. You can view the full earnings history and future projections here: iRhythm Earnings and Analyst Estimates.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Please consult with a financial professional before making any investment decisions.